MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing

European Journal of Immunology

Volumn 37, Issue 7, 2007, Pages 2008-2017

  Held, Gerhard ^a   Wadle, Andreas ^b   Dauth, Nina ^a   Stewart Jones, Guillaume ^c   Sturm, Christine ^a   Thiel, Markus ^b   Zwick, Carsten ^a   Dieckmann, Detlef ^d   Schuler, Gerold ^d   Hoogenboom, Hennie R ^e,g   Lévy, Frédéric ^f   Cerundolo, Vincenzo ^c   Pfreundschuh, Michael ^a   Renner, Christoph ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e Dyax SA   (Belgium)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g ABLYNX NV   (Belgium)

Author keywords

Antigen presentation; CTL; MHC peptide complexes; Peptide processing; Phage library

Indexed keywords

EPITOPE; GREEN FLUORESCENT PROTEIN; HLA A ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; MUTANT PROTEIN; UBIQUITIN;

ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CELL SURFACE; COMPLEX FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA CELL; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; VACCINIA VIRUS; VIRUS RECOMBINANT; WILD TYPE;

EID: 34447515469     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200636545     Document Type: Article

References (52)

1. Coulie, P. G., Brichard, V., Van Pel, A., Wolfel, T., Schneider, J., Traversari, C., Mattei, S. et al., A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 1994. 180: 35-42.
2. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Mild, T. and Rosenberg, S. A., Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 1994. 91: 3515-3519.
3. Romero, P., Gervois, N., Schneider, J., Escobar, P., Valmori, D., Pannetier, C., Steinle, A. et al., Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/ MART-1 antigenic peptide in melanoma. J. Immunol. 1997. 159: 2366-2374.
4. Valmori, D., Fonteneau, J. F., Lizana, C. M., Gervois, N., Lienard, D., Rimoldi, D., Jongeneel, V. et al., Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 1998. 160: 1750-1758.
5. b transgenic mice. J. Immunol. 1999. 162: 3566-3573.
6. Valmori, D., Levy, F., Miconnet, I., Zajac, P., Spagnoli, G. C., Rimoldi, D., Lienard, D. et al., Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J. Immunol. 2000. 164: 1125-1131.
7. Jaeger, E., Bernhard, H., Romero, P., Ringhoffer, M., Arand, M., Karbach, J., Ilsemann, C. et al., Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer 1996. 66: 162-169.
8. Pullarkat, V., Lee, P. P., Scotland, R., Rubio, V., Groshen, S., Gee, C., Lau, R. et al., A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin. Cancer Res. 2003. 9: 1301-1312.
9. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 2005. 115: 739-746.
10. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 2002. 99: 16168-16173.
11. Meidenbauer, N., Marienhagen, J., Laumer, M., Vogl, S., Heymann, J., Andreesen, R. and Mackensen, A., Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J. Immunol. 2003. 170: 2161-2169.
12. Smith, C. L., Mirza, F., Pasquetto, V., Tscharke, D. C., Palmowski, M. J., Dunbar, P. R., Sette, A. et al., Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J. Immunol. 2005. 175: 8431-8437.
13. Smith, C. L., Dunbar, P. R., Mirza, F., Palmowski, M. J., Shepherd, D., Gilbert, S. C., Coulie, P. et al., Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int. J. Cancer 2005. 113: 259-266.
14. Vignard, V., Lemercier, B., Lim, A., Pandolfino, M. C., Guilloux, Y., Khammari, A., Rabu, C. et al., Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J. Immunol. 2005. 175: 4797-4805.
15. Rimoldi, D., Muehlethaler, K., Salvi, S., Valmori, D., Romero, P., Cerottini, J. C. and Levy, F., Subcellular localization of the melanoma-associated protein Melan-AMART-1 influences the processing of its HLA-A2-restricted epitope. J. Biol. Chem. 2001. 276: 43189-43196.
16. Chapatte, L., Servis, C., Valmori, D., Burlet-Schiltz, O., Dayer, J., Monsarrat, B., Romero, P. and Levy, F., Final antigenic Melan-A peptides produced directly by the proteasomes are preferentially selected for presentation by HLA-A*0201 in melanoma cells. J. Immunol. 2004. 173: 6033-6040.
17. Morel, S., Levy, F., Burlet-Schiltz, O., Brasseur, F., Probst-Kepper, M., Peitrequin, A. L., Monsarrat, B. et al., Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000. 12: 107-117.
18. Sykulev, Y., Joo, M., Vturina, I., Tsomides, T. J. and Eisen, H. N., Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 1996. 4: 565-571.
19. Irvine, D. J., Purbhoo, M. A., Krogsgaard, M. and Davis, M. M., Direct observation of ligand recognition by T cells. Nature 2002. 419: 845-849.
20. Purbhoo, M. A., Irvine, D. J., Huppa, J. B. and Davis, M. M., T cell killing does not require the formation of a stable mature immunological synapse. Nat. Immunol. 2004. 5: 524-530.
21. Aharoni, R., Teitelbaum, D., Arnon, R. and Puri, J., Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen-Ia complex. Nature 1991. 351: 147-150.
22. Dadaglio, G., Nelson, C. A., Deck, M. B., Petzold, S. J. and Unanue, E. R., Characterization and quantitation of peptide-MHC complexes produced. from hen egg lysozyme using a monoclonal antibody. Immunity 1997. 6: 727-738.
23. Porgador, A., Yewdell, J. W., Deng, Y., Bennink, J. R. and Germain, R. N., Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997. 6: 715-726.
24. Zhong, G., Reis e Sousa, C. and Germain, R. N., Production, specificity, and functionality of monoclonal antibodies to specific peptide-major histocompatibility complex class II complexes formed by processing of exogenous protein. Proc. Natl. Acad. Sci. USA 1997. 94: 13856-13861.
25. Chames, P., Hufton, S. E., Coulie, P. G., Uchanska-Ziegler, B. and Hoogenboom, H. R., Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc. Natl. Acad. Sci. USA 2000. 97: 7969-7974.
26. Cohen, C. J., Hoffmann, N., Farago, M., Hoogenboom, H. R., Eisenbach, L. and Reiter, Y., Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Res. 2002. 62: 5835-5844.
27. Denkberg, G., Cohen, C. J., Lev, A., Chames, P., Hoogenboom, H. R. and Reiter, Y., Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. Proc. Natl. Acad. Sci. USA 2002. 99: 9421-9426.
28. Lev, A., Denkberg, G., Cohen, C. J., Tzukerman, M., Skorecki, K. L., Chames, P., Hoogenboom, H. R. and Reiter, Y., Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res. 2002. 62: 3184-3194.
29. Cohen, C. J., Sarig, O., Yamano, Y., Tomaru, U., Jacobson, S. and Reiter Y., Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies. J. Immunol. 2003. 170: 4349-4361.
30. Held, G., Matsuo, M., Epel, M., Gnjatic, S., Ritter, G., Lee, S. Y., Tai, T. Y. et al., Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Eur. J. Immunol. 2004. 34: 2919-2929.
31. Villanueva, M. S., Fischer, P., Feen, K. and Pamer, E. G., Efficiency of MHC class I antigen processing: a quantitative analysis. Immunity 1994. 1: 479-489.
32. Sijts, A. J., Neisig, A., Neefjes, J. and Pamer, E. G., Two Listeria monocytogenes CTL epitopes are processed from the same antigen with different efficiencies. J. Immunol. 1996. 156: 683-692.
33. Princiotta, M. F., Finzi, D., Qian, S. B., Gibbs, J., Schuchmann, S., Buttgereit, F., Bennink, J. R. and Yewdell, J. W., Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 2003. 18: 343-354.
34. Skipper, J. C., Gulden, P. H., Hendrickson, R. C., Harthun, N., Caldwell, J. A., Shabanowitz, J., Engelhard, V. H. et al., Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int. J. Cancer 1999. 82: 669-677.
35. Subbramanian, R. A., Moriya, C., Martin, K. L., Peyerl, F. W., Hasegawa, A., Naoi, A., Chhay, H. et al., Engineered T-cell receptor tetramers bind MHC-peptide complexes with high affinity. Nat. Biotechnol. 2004. 22: 1429-1434.
36. Engelhard, V. H., Brickner, A. G. and Zarling, A. L., Insights into antigen processing gained by direct analysis of the naturally processed class I MHC associated peptide repertoire. Mol. Immunol. 2002. 39: 127-137.
37. Levy, F., Johnsson, N., Rumenapf, T. and Varshavsky, A., Using ubiquitin to follow the metabolic fate of a protein. Proc. Natl. Acad. Sci. USA 1996. 93: 4907-4912.
38. Valmori, D., Gileadi, U., Servis, C., Dunbar, P. R., Cerottini, J. C., Romero, P., Cerundolo, V. and Levy, F., Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J. Exp. Med. 1999. 189: 895-906.
39. Frisan, T., Levitsky, V., Polack, A. and Masucci, M. G., Phenotype-dependent differences in proteasome subunit composition and cleavage specificity in B cell lines. J. Immunol. 1998. 160: 3281-3289.
40. De Maziere, A. M., Muehlethaler, K., van Donselaar, E., Salvi, S., Davoust, J., Cerottini, J. C., Levy, F. et al., The melanocytic protein Melan-A/MART-1 has a subcellular localization distinct from typical melanosomal proteins. Traffic 2002. 3: 678-693.
41. Reits, E. A., Vos, J. C., Gramme, M. and Neefjes, J., The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 2000. 404: 774-778.
42. Schubert, U., Anton, L. C., Gibbs, J., Norbury, C. C., Yewdell, J. W. and Bennink, J. R., Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000. 404: 770-774.
43. Khan, S., de Giuli, R., Schmidtke, G., Bruns, M., Buchmeier, M., van den Broek, M. and Groettrup, M., Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein. J. Immunol. 2001. 167: 4801-4804.
44. Reits, E., Griekspoor, A., Neijssen, J., Groothuis, T., Jalink, K., van Veelen, P., Janssen, H. et al., Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity 2003. 18: 97-108.
45. Neefjes, J. J., Momburg, F. and Hammerling, G. J., Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 1993. 261: 769-771.
46. Ortmann, B., Copeman, J., Lehner, P. J., Sadasivan, B., Herberg, J. A., Grandea, A. G., Riddell, S. R. et al., A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science 1997. 277: 1306-1309.
47. Saric, T., Chang, S. C., Hattori, A., York, I. A., Markant, S., Rock, K. L., Tsujimoto, M. and Goldberg, A. L., An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat. Immunol. 2002. 3: 1169-1176.
48. Serwold, T., Gonzalez, F., Kim, J., Jacob, R. and Shastri, N., ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 2002. 419: 480-483.
49. Altman, J. D., Moss, P. A., Goulder, P. J., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J. and Davis, M. M., Phenotypic analysis of antigen-specific T lymphocytes. Science 1996. 274: 94-96.
50. Hoet, R. M., Cohen, E. H., Kent, R. B., Rookey, K., Schoonbroodt, S., Hogan, S., Rem, L. et al., Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat. Biotechnol. 2005. 23: 344-348.
51. de Haard, H. J., van Neer, N., Reurs, A., Hufton, S. E., Roovers, R. C., Henderikx, P., de Bruine, A. P. et al., A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. 1999. 274: 18218-18230.
52. Henderikx, P., Kandilogiannaki, M., Petrarca, C., von Mensdorff-Pouilly, S., Hilgers, J. H., Krambovitis, E., Arends, J. W. and Hoogenboom, H. R., Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma. Cancer Res. 1998. 58: 4324-4332.